4.7 Article

Pharmacologically induced reversible hypometabolic state mitigates radiation induced lethality in mice

Journal

SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41598-017-15002-7

Keywords

-

Funding

  1. Defence Research and Development Organization, Delhi, India

Ask authors/readers for more resources

Therapeutic hypothermia has proven benefits in critical care of a number of diseased states, where inflammation and oxidative stress are the key players. Here, we report that adenosine monophosphate (AMP) triggered hypometabolic state (HMS), 1-3 hours after lethal total body irradiation (TBI) for a duration of 6 hours, rescue mice from radiation-induced lethality and this effect is mediated by the persistent hypothermia. Studies with caffeine and N-6-cyclohexyladenosine, a non-selective antagonist and a selective agonist of adenosine A1 receptor (A1AR) respectively, indicated the involvement of adenosine receptor (AR) signaling. Intracerebroventricular injection of AMP also suggested possible involvement of central activation of AR signaling. AMP, induced HMS in a strain and age independent fashion and did not affect the behavioural and reproductive capacities. AMP induced HMS, mitigated radiation-induced oxidative DNA damage and loss of HSPCs. The increase in IL-6 and IL-10 levels and a shift towards anti-inflammatory milieu during the first 3-4 hours seems to be responsible for the augmented survival of HSPCs. The syngeneic bone marrow transplantation (BMT) studies further supported the role of radiation-induced inflammation in loss of bone marrow cellularity after TBI. We also showed that the clinically plausible mild hypothermia effectively mitigates TBI induced lethality in mice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists

Jayadev Joshi, Manali Dimri, Subhajit Ghosh, Nitisha Shrivastava, Rina Chakraborti, Neeta Sehgal, Jharna Ray, Indracanti Prem Kumar

CURRENT COMPUTER-AIDED DRUG DESIGN (2015)

Article Immunology

Rescuing Self: Transient Isolation and Autologous Transplantation of Bone Marrow Mitigates Radiation-Induced Hematopoietic Syndrome and Mortality in Mice

Subhajit Ghosh, Namita Indracanti, Jayadev Joshi, Prem Kumar Indraganti

FRONTIERS IN IMMUNOLOGY (2017)

Article Engineering, Environmental

Evaluation of biological and cytocompatible properties in nano silver-clay based polyethylene nanocomposites

Anasuya Roy, Mangala Joshi, B. S. Butola, Subhajit Ghosh

JOURNAL OF HAZARDOUS MATERIALS (2020)

Article Oncology

Long-Acting Recombinant Human Interleukin-7, NT-17, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

Jian L. Campian, Subhajit Ghosh, Vaishali Kapoor, Ran Yan, Sukrutha Thotala, Arijita Jash, Tong Hu, Anita Mahadevan, Kasem Rifai, Logan Page, Byung Ha Lee, Sara Ferrando-Martinez, Alexandra A. Wolfarth, Se Hwan Yang, Dennis Hallahan, Milan G. Chheda, Dinesh Thotala

Summary: In this study, NT-17 was found to prevent systemic lymphopenia in GBM patients receiving radiotherapy and temozolomide, while improving survival. Furthermore, NT-17 increased cytotoxic CD8 T lymphocytes in lymphoid organs and tumor.

CLINICAL CANCER RESEARCH (2022)

Article Cell Biology

Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma

Subhajit Ghosh, Jiayi Huang, Matthew Inkman, Jin Zhang, Sukrutha Thotala, Ekaterina Tikhonova, Natalia Miheecheva, Felix Frenkel, Ravshan Ataullakhanov, Xiaowei Wang, David DeNardo, Dennis Hallahan, Dinesh Thotala

Summary: Severe and prolonged lymphopenia often occurs in glioblastoma patients after standard chemoradiotherapy, and it is associated with worse survival. A correlative study was conducted on 20 patients with glioblastoma to investigate the underlying biological mechanism of lymphopenia. The study revealed an elevated concentration of myeloid-derived suppressor cell (MDSC) regulatory genes in patients with lymphopenia after chemoradiotherapy. Further analysis confirmed increased numbers of circulating MDSC in these patients, and preclinical models demonstrated a causal relationship between radiation-induced MDSC and systemic lymphopenia. Pharmacological inhibition of MDSC effectively prevented radiation-induced lymphopenia and improved survival in the models, suggesting the potential of CB1158 and tadalafil as drugs for reducing lymphopenia in glioblastoma patients.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Medicine, Research & Experimental

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production

Liyun Chen, Victoria Shi, Songyan Wang, Lulu Sun, Rebecca Freeman, Jasmine Yang, Matthew J. Inkman, Subhajit Ghosh, Fiona Ruiz, Kay Jayachandran, Yi Huang, Jingqin Luo, Jin Zhang, Pippa Cosper, Clifford J. Luke, Catherine S. Spina, Perry W. Grigsby, Julie K. Schwarz, Stephanie Markovina

Summary: Patients with high levels of SERPINB3 in their serum commonly experience treatment resistance and poor prognosis in cancer. The role of SERPINB3 in tumor immunity is not well understood. Through experiments on human primary cervical tumors and mouse models, it was found that SERPINB3 promoted myeloid cell infiltration and inhibited T cell function, leading to treatment resistance. Inhibition of SERPINB3 enhanced cytotoxic T cell function and improved the response to radiotherapy. These findings suggest that targeting SERPINB3 may be a potential strategy to counteract immunosuppression and improve treatment response in tumors.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Meeting Abstract Oncology

Association of circulating myeloid derived suppressor cells with systemic lymphopenia following chemoradiotherapy in glioblastoma.

Subhajit Ghosh, Matthew Inkman, Jin Zhang, Sukrutha Thotala, Ekaterina Tikhonova, Natalia Miheecheva, Felix Frenkel, Ravshan Ataullakhanov, Xiaowei Wang, Dennis Hallahan, Jiayi Huang, Dinesh Thotala

CANCER RESEARCH (2021)

Meeting Abstract Oncology

A NOVEL LONG-ACTING INTERLEUKIN-7 AGONIST, NT-I7, INCREASES CYTOTOXIC CD8+T CELLS AND ENHANCES SURVIVAL IN MOUSE GLIOMA MODELS

Subhajit Ghosh, Ran Yan, Sukrutha Thotala, Arijita Jash, Anita Mahadevan, Tong Hu, Byung Lee, Se Hwan Yang, Dennis Hallahan, Milan Chheda, Dinesh Thotala, Jian Campian

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Meeting Abstract Oncology

A NOVEL LONG-ACTING INTERLEUKIN-7 AGONIST, NT-I7, INCREASES CYTOTOXIC CD8 CELLS AND ENHANCES SURVIVAL IN MOUSE GLIOMA MODELS

Subhajit Ghosh, Ran Yan, Sukrutha Thotala, Arijita Jash, Anita Mahadevan, Tong Hu, Byung Ha Lee, Se Hwan Yang, Dennis Hallahan, Milan Chheda, Dinesh Thotala, Jian Campian

NEURO-ONCOLOGY (2020)

Article Chemistry, Medicinal

Cycloxygenase-2 (COX-2) - A Potential Target for Screening of Small Molecules as Radiation Countermeasure Agents: An In Silico Study

Jayadev Joshi, Tapan K. Barik, Nitisha Shrivastava, Manali Dimri, Subhajit Ghosh, Rahul S. Mandal, Srinivasan Ramachandran, Indracanti P. Kumar

CURRENT COMPUTER-AIDED DRUG DESIGN (2013)

No Data Available